Amneal Pharmaceuticals (AMRX): Time to Buy this HEALTHY Growth Stock

This is the first Stock of the Week commentary for 2026. So I wanted to share something special to kick off the new year. This led me to select Amneal Pharmaceuticals (AMRX). 

There is a lot to love about this stock which compelled me to put together this recent video featuring AMRX explaining why I think it could double or more in the year ahead. 

Perhaps the best  place to start is that it is the highest Zen Rated stock in my Zen Investor portfolio. 

Not just an A rated stock putting it in the top 5% we analyze. But actually in the top 0.5% of all stocks analyzed. (More specifics on the ratings further below). 

Another good reason to consider AMRX is that I recently increased my allocation to healthcare stocks. That’s because the easy gains stage of this aging bull market is now over. 

Now it will likely be a more volatile path forward. Kind of like 2 steps forward and 1 step back. 

One of the best groups to navigate that extra volatility is healthcare. Especially a growth oriented company like  that will have appeal during times of greed as well as fear. 

Let’s focus on that growth story. 

Right now they are expected to grow earnings 38% year over year. For as strong as that sounds, please remember they have averaged a 33% beat the past few quarters. So likely earnings growth will end up even higher than expected. 

One major growth catalyst has been the launch of CREXONT (for Parkinson’s disease), which management highlighted as a standout contributor. Other newer products, including injectable and complex medicines (not just plain tablets), are also gaining traction. 

All in all, the che company leverages its ability to make “complex dosage forms” — injectables, inhalants, ophthalmics, etc. — which limits competition and tends to command better margins. 

Lets get back to the impressive Zen Ratings putting it in the 99.56th percentile out of nearly 4,600 in our model. 

This is a story of having no weakness across the 7 component grades with the following strengths:

Top 20% Financials

Top 14% Value

Top 10% Growth

Top 9% Momentum

Top 4% Sentiment

Add it all together and you can easily appreciate my excitement in AMRX. 

Truly it has the look of a stock with the potential to double in the next couple of years given its special fundamental profile. This is especially true if it keeps up those robust 33% earnings beats. 

What To Do Next?

Amneal Pharmaceuticals (AMRX) is just one of 20 stellar stocks found in my Zen Investor portfolio.

Each stock was selected by harnessing the power of the Zen Ratings along with my 45 years of successful investing experience. 

This dynamic combination has me pinpointing stocks with the unique opportunity to double or more in the next 1-2 years. 

IMPORTANT NOTE: On Wednesday January 14th I am adding 2 new stocks to the Zen Investor portfolio ready to beat the market in 2026. 

The only way to see all these stocks is to become a Zen Investor member. 

Gladly that is a fairly easy process and a great way to kick off 2026. Just click below to learn more…

Discover the Zen Investor & Top 20 Stocks Now > 

Wishing you a world of investment success!

Steve Reitmeister…but everyone calls me Reity (pronounced “Righty”)

Editor of the Zen Investor

Want to get in touch? Email us at news@wallstreetzen.com.